CINCINNATI, March 9 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the implementation of a new biostatistics infrastructure that will significantly enhance the analysis and delivery of quality clinical trial data for customers. The centralized SAS®-based platform provides a virtual environment allowing for simultaneous access and analysis of clinical trial data by Kendle's global Biostatistics and Scientific Programming teams from anywhere in the world, creating significant time savings and further enhancing data security. The launch of the new system will be seamless to customers.
"With this new environment data will be processed at the server level much faster than ever before, greatly improving the productivity of our teams around the world and expediting the delivery of quality data to our customers," said John A. Whitaker, Ph.D., Vice President, Biostatistics and Statistical Programming. "This investment allows Kendle to provide a more globally integrated solution to meet our customers' needs anywhere, any time."
In addition to improved efficiency, quality and security, the centralized platform also positions Kendle to better leverage its growing operations in India. Other benefits of the new infrastructure implementation include improved network performance and bandwidth availability; reduced licensing requirements; and simplification of the testing, production and recovery environments.
Kendle's Biostatistics and Scientific Programming team is comprised of a worldwide network of experts utilizing globally consistent processes to maximize operating efficiencies and ensure delivery of the highest quality data analysis and reporting to our customers. The team specializes in the planning and execution of meaningful analyses of even the most complex clinical trials. Kendle is equipped to provide actionable data as either a functional service or full service provider, and is currently involved in statistical services worldwide.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.
Certain statements and information contained in this press release may be deemed to be forward-looking statements under federal securities laws and the provisions of the Private Securities Litigation Reform Act of 1995 and Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. All such forward-looking statements, including the statements contained herein regarding anticipated trends from Kendle's implementation of the SAS® server-based solution are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those risks as detailed from time to time in Kendle's Annual Report on Form 10-K as well as periodic reports filed with the SEC. All information in this press release is current as of March 9, 2010. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.
SOURCE Kendle International Inc.Back to top
|SOURCE Kendle International Inc.|
Copyright©2010 PR Newswire.
All rights reserved